Chembond Chemicals Ltd

Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.

Chembond Chemicals Ltd trades at ₹262, in a confirmed uptrend and 16 weeks into that stage. That is +29.5% against its own 200-day average. It sits at 80% of a 52-week range of ₹173 to ₹284. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 7 straight weeks.

Today the stock is in a confirmed uptrend — week 16 of stage 2, confirmed. At ₹262 it trades +29.5% versus its 200-day average and sits at 80% of its 52-week range (₹173–₹284).

Against the market, two honest reads. Cumulative: over the last 4 months the stock moved +40% while the NIFTY 500 moved +1% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 7 straight weeks — the ribbon below is that same metric, week by week.

What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.

Story check

Chembond Chemicals Ltd's story is not scored yet against the markers our research file set on 19 July 2026. Where it sits in its own cycle: Not stated in the research file. Our fortnightly research layers last read it on 22 August 2026.

Our read, 19 July 2026. Post-demerger specialty chemicals compounder gaining water-treatment scale, now facing a material-cost squeeze that will test whether 4 quarters of volume momentum can survive a margin step-down.

From the numbers. PE at 17-18x on trailing earnings places the stock near the 50th percentile of its limited PE history (only 1 data point available in the 40-quarter series). The PE cycle label is EMERGING_OPPORTUNITY with a COMPRESSED…

From the price. Price stage 2, week 16 — above its 200-day line, relative strength rising.

From the research. Post-demerger specialty chemicals compounder gaining water-treatment scale, now facing a material-cost squeeze that will test whether 4 quarters of volume momentum can survive a margin step-down.

🚨 Where they disagree. PE at 17-18x on trailing earnings places the stock near the 50th percentile of its limited PE history (only 1 data point available in the 40-quarter series). The PE cycle label is EMERGING_OPPORTUNITY with a COMPRESSED cycle position — the stock is trading near its median multiple with limited history to determine the true cycle position. The deterministic cycle verdict is NA_SHORT_MARGIN_HISTORY: with only 2.3 years of OPM data, the normalized-PE calculation cannot anchor to a meaningful mid-cycle margin, making the cycle verdict informationally limited. ROCE at 24% is at the 87th percentile of its 5-year history, indicating the business is currently at a high return-on-capital phase…

What is proven. Post-demerger specialty chemicals compounder gaining water-treatment scale, now facing a material-cost squeeze that will test whether 4 quarters of volume momentum can survive a margin step-down.

What is not proven yet. If debtor days exceed 140 by Sep 2026 while revenue growth is below 10% — signaling the receivables build is channel-credit rather than business-model scaling — or if the April 2026 contract renewals fail to show OPM recovery above 15% in the Dec 2026 quarter despite management's pass-through narrative, the thesis breaks.

🚨 What would change our mind. If debtor days exceed 140 by Sep 2026 while revenue growth is below 10% — signaling the receivables build is channel-credit rather than business-model scaling — or if the April 2026 contract renewals fail to show OPM recovery above 15% in the Dec 2026 quarter despite management's pass-through narrative, the thesis breaks.

🚨 Layer 1 read, 22 August 2026 — DROP. Sales and profit are genuinely growing, but the cash never arrives and the price already sits at its high. Chembond's June quarter was strong and, importantly, operations-driven: sales up 32.3% and profit up 52.3% on the year, with operating profit up 34.6% rather than the gain coming from one-off items. The cost squeeze management warned about is visible where they buy raw materials — gross margin fell from 48.93% to 43.69% — but it has not yet reached the profit line. The problem is cash: across three years the company reported Rs 96 crore of profit while its operations gave back minus Rs 38 crore of cash, because customers now take 128 days to pay against 94 four years ago. With the share up 57% in a year and sitting at its own high, you are paying full price for profits that have not yet…

What would change Layer 1’s mind. Debtor days breaking 140 in the September or December 2026 quarter while revenue growth falls below 10% — that pairing would turn the receivables build from business-model scaling into credit-quality damage and is the Timeline's own stated breaker. The second is operating margin printing below 12.9% in the September 2026 quarter, which would mean the April-2026 contract renewals failed to pass the zinc and molybdenum costs through and the gross-margin squeeze has finally reached the operating…

What the company does. Chembond is a niche water-treatment chemicals provider with 87% revenue concentration, 45+ years of client lock-in, and a recent volume surge that pushed FY26 revenue to 326 Cr. A post-war spike in zinc and molybdenum costs compressed EBITDA margins by 3 percentage points heading into FY27. The thesis rests on whether contract renewals in April 2026 pass through the elevated costs before volumes moderate from their H2 FY26 peak.

🚨 What the surface reading misses. The surface reading is: Wide OPM range signals volatile earnings quality. The research reads it further: The range is an operating-leverage artifact and mix effect. Dec 2024 spike to 19.24% OPM versus Sep 2024's 10.54% in consecutive quarters suggests the business has high fixed-cost operating leverage. GPM ranged from 43-53% over the same period — gross margin is more stable, confirming the OPM swing is employee-cost and opex leverage, not input-cost volatility alone.

🚨 What the surface reading misses. The surface reading is: High ROCE indicates quality business — consider as a positive. The research reads it further: ROCE at the 87th percentile of own history, coinciding with the MID_EXPANSION operating cycle stage, raises the peak-cyclical flag. However, ROCE improvement from 11% (FY23) to 24-26% (FY25-26) reflects the demerger simplification — the consolidated entity post-demerger has less capital overhead from the previously larger combined balance sheet. Pre-demerger FY22-23 ROCE of 11% included manufacturing assets now excluded. The high ROCE is partly structural (better capital efficiency post-demerger) and partly cyclical (high-volume period).

Sources: our stock research file (19 July 2026) · quarterly results through Jun 26 · the company’s own earnings calls. The story check is re-scored every results season; the record below never changes.

Revenue Revenue is the top line: everything the company billed its customers in the period.

Chembond Chemicals Ltd reported ₹86.5 Cr of revenue in the Jun 26 quarter, +32.3% year on year. That is the 3rd straight quarter of year-on-year growth. Over 4 years it has compounded at −1.7% a year. The last full year, FY26, came in at ₹326 Cr. The last four reported quarters add to ₹347 Cr.

Why this happened. The water business signed new customers in H2 FY26 that brought H2 volume to 14813 MT — up 50% from 9905 MT in H1. These customers are on multi-quarter contracts with visibility through mid-FY27. The retention rate on existing contracts is 65% of the business, providing a durable volume floor. Even at 10% FY27 volume growth — management's own moderated guidance — the water segment generates a material step-up in revenue at current prices.

FY26 revenue came in at ₹326 Cr (+11.6% on the year), capping 4 years at −1.7% compound. The latest quarter (Jun 26) printed ₹86.5 Cr, +32.3% year on year — the 3rd consecutive quarter of year-over-year growth.

Pace check: the last four quarters averaged +18.7% growth against the decade's −1.7% — the current year is running faster than its own long-run rate.

Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.

Chembond Chemicals Ltd's operating margin is 13.1% in the Jun 26 quarter, +0.2 percentage points against the same quarter a year ago. That is the widest this company has ever printed on a full-year basis. Across 5 fiscal years the operating margin has ranged 4.9% to 15.0%. The current quarter sits inside that band.

Why this happened. Management activated force majeure, secured temporary 3-month pricing increments from private-sector customers (70% of water revenue), and is rebidding public-sector contracts at current material costs. April 2026 was described as the renewal window for many contracts. If input-cost pressures plateau or soften by Q3 FY27, the margin recovery timeline of 2-3 quarters maps to an OPM recovery in Dec 2026-Mar 2027.

The latest quarter's operating margin is 13.1%, +0.2 pp against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 4.9%–15.0%, and FY26's 15.0% is the top of that band — a record year.

Why the margin moved: operating margin went +0.2 pp year on year while gross margin went −9.8 pp — the gain came mostly from the gross line: input costs and pricing.

Worth repeating from the valuation section: cheap against its own history on record margins is not the same thing as cheap — a record margin flatters every ratio built on top of it.

Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.

Chembond Chemicals Ltd earned ₹9.6 Cr of net profit in the Jun 26 quarter, +52.3% year on year. It is the 2nd consecutive quarter of growth. Full-year FY26 profit was ₹35.0 Cr. The 4-year compound rate is 25.7%. That is 11.0% of the quarter's revenue. The same quarter a year earlier earned ₹6.3 Cr.

Jun 26 profit was ₹9.6 Cr, +52.3% year on year — the 2nd consecutive quarter of growth. On the full year, FY26 printed ₹35.0 Cr (+12.9%), and the 4-year compound rate is 25.7%.

Why profit moved: revenue contributed +32.3% and the margin +0.2 pp — the quarter was revenue-led, with the margin roughly flat.

Pace comparison, last four quarters: profit +22.0% vs revenue +18.7%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra rupee of revenue drops more to the bottom line.

Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.

Over the last 3 fiscal years −40% of Chembond Chemicals Ltd's reported profit arrived as operating cash — a gap worth watching. In FY26 that was ₹8.0 Cr of operating cash against ₹35.0 Cr of profit. After ₹7.0 Cr of capital spending, ₹1.0 Cr was left as free cash.

FY26: operating cash of ₹8.0 Cr against reported profit of ₹35.0 Cr, leaving free cash of ₹1.0 Cr after ₹7.0 Cr of capital spending. Across the last 3 fiscal years the conversion rate is −40% of profit.

Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.

🚨 Why conversion sits at −40%: the cash cycle stretched 25 days between FY22 and FY26 — more of each rupee of profit waits inside the cycle before arriving. Less than 70% of profit arriving as cash is the thing to watch on this page.

Router verdict: conversion is below par and the cash cycle has stretched 25 days — the next section's job is to find where the cash is stuck.

Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).

Chembond Chemicals Ltd's cash conversion cycle runs 109 days in FY26, up from 84 days in FY22. Capital spending ran ₹−93.0 Cr over the last 3 years. At FY26 sales of ₹326 Cr each day of that cycle holds about ₹0.9 Cr, so roughly ₹97.0 Cr sits inside the business at any moment.

FY26: debtors at 128 days, inventory at 57 days — roughly 1.9 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 109 days, looser than FY22's 84.

The full loop: cash goes out to suppliers and production on day 0; stock waits 57 days to sell; customers pay about 128 days after that; and suppliers themselves are paid at 75 days — netting out to the 109-day cycle.

In money terms: at FY26 sales of ₹326 Cr, each day of the cycle holds about ₹0.9 Cr — so the 109-day loop keeps roughly ₹97.0 Cr sitting inside the business at any moment.

On the investment side: capital spending of ₹−93.0 Cr over the last 3 fiscal years against ₹13.0 Cr of depreciation — spending at or below maintenance level. Capital work-in-progress stands at ₹0.0 Cr (FY26) — capacity paid for but not yet earning.

The synthesis: the working-capital loop is the cash sink the router flagged — watch the cycle, not the P&L.

Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.⚠ unverified

Chembond Chemicals Ltd earns a ROCE of 24% in FY26. That is up from a trough of 11% in FY23. Return on invested capital clears the cost of that capital by +12.7 percentage points, so growth here adds value rather than only size. The wiring behind it is 10.7% net margin on 1.29× asset turns.

FY26 ROCE is 24%, recovered from a FY23 trough of 11% — the full ladder below shows the fall and the climb, undoctored.

Why the return is what it is — the wiring (FY26): 10.7% net margin × 1.29× asset turns × 1.22× balance-sheet leverage ≈ 16.8% on equity. Margin does its share; leverage is modest — this is an earned return, not a borrowed one.

The capstone test — ROIC − WACC: 24.7% − 12.0% = a +12.7 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. A spread this wide means every rupee reinvested creates more than a rupee of value — the engine compounds.

Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.⚠ unverified

Chembond Chemicals Ltd carries total debt of ₹7.0 Cr against shareholder equity of ₹363 Cr as of Jun 24, a debt-to-equity of 0.02 — effectively unlevered. On the annual view that ratio went from 0.01 in FY22 to 0.02 in FY23. The returns elsewhere on this page are therefore earned rather than borrowed.

Jun 24: total debt of ₹7.0 Cr against shareholder equity of ₹363 Cr — a debt-to-equity of 0.02. On the annual view, debt-to-equity went from 0.01 (FY22) to 0.02 (FY23). The returns on this page are earned, not borrowed.

Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.

Domestic institutions added 1.7 points of Chembond Chemicals Ltd over 4 quarters, the biggest move on the register. That takes domestic institutions to 2.6% of the company. Promoters moved +0.3 points over the same window, to 68.0%. The register is read on the four disclosed classes only; nothing is inferred between filings.

The register over the last two years — Domestic institutions: +1.7 points over 4 quarters to 2.6%; Promoters: +0.3 points over 4 quarters to 68.0%; Foreign institutions: +0.0 points over 4 quarters to 0.7%.

Why the register moved: domestic institutions drove it (+1.7 points) — steady accumulation by institutions reading the same numbers this page reads.

Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.

Chembond Chemicals Ltd: the Z-score reads 9.28. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits well clear of distress. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.

Why it matters: a Z-score of 9.28 sits well clear of the distress zone — the balance sheet is not the risk here.

The safety line in one sentence: the Z-score reads 9.28.

Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.

Chembond Chemicals Ltd trades at 18.4× P/E, at the pricey end of its own range (75th percentile). Its long-run median P/E is 17.3×, measured across 0.3 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.

Today's P/E of 18.4× is at the pricey end of its own range (75th percentile), against a long-run median of 17.3× measured over 0.3 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.

Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.

A quarterly PEG curve, which only the second data source carries, is not drawn on this page: its two data sources do not share enough overlapping reported history to be compared. A figure nobody could check is not used to price growth — the gap is a decision, not missing data.

What the price assumes This reading works the multiple backwards. It asks one question: what yearly rate of profit growth is a buyer at the market price already paying for? The number is the growth rate that makes eleven years of profit — six years growing, then five fading — add up to that day's market price, once each year is discounted at 11% a year.

Solved at its 27 August 2026 price, Chembond Chemicals Ltd was paying for profit growth of about 10.8% a year. Profit itself has compounded 25.7% a year over the past 4 years. Today the market pays 18.4× P/E, the 75th percentile of its own 0-year range.

What the two numbers say together. The multiple is full against its own past, and the growth the price is paying for is below what this company has actually delivered.

How to hold this number: it is a reading of one day's price, taken on 27 August 2026, not a running figure — every other number on this page, the multiple included, is read off the live quote as of 11 September 2026. A higher price is paying for more growth and a lower price for less, so it moves whenever the price does, and this page does not restate it between measurements.

Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).

Chembond Chemicals Ltd reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read. The read is built from 5 quarters across 1 curve, on partial evidence.

Why it matters: with too little history, an honest page says so instead of guessing a trajectory.

One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.

Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.

Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.

4-Factor Sector Score

56.6/100 — rank 2 of 5 in Chemicals - Speciality · 62% evidence confidence

Chembond Chemicals Ltd scores 56.6 out of 100 against the 5 companies it is compared with in Chemicals - Speciality, ranking 2. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.

The four contributions add to the total exactly: 20 + 14.1 + 10 + 12.5 = 56.6. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.

What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.

Said versus delivered

What Chembond Chemicals Ltd's management promised, set against what actually arrived — 4 tracked promises on the record. Read straight from the company’s own earnings calls. A promise that slipped stays on this page after it is met.

🚨 Failed Recovery in Construction Chemicals · 16 May 2026. During the Nov 2025 call, management stated that although construction chemicals were down 6% in the first half due to a prolonged monsoon, the trend was already reversing and they expected a much stronger second half with a higher share of total revenue. However, in the May 2026 call, management reported a 15% year-over-year revenue decrease for the full year, admitting that the same monsoon timeframe significantly impacted projects and contradicting the earlier growth narrative.

Margin and Cost Management Narrative Shift · 16 May 2026. During the Nov 2025 call, management characterized their profit margins as stable and attributed earnings improvements to lower raw material costs and cost optimization. By the May 2026 call, the tone shifted to profit protection and rationing as they admitted a 3% margin decrease and labeled profitability as a current challenge due to surging metal costs that forced the company to declare force majeure.

Moderated Growth Outlook for Water Segment · 16 May 2026. In the Nov 2025 call, management expressed confidence that the core water treatment chemicals business would grow at a steady rate of 10% to 15% annually. In the May 2026 call, management moderated this guidance to roughly 10% for the upcoming year, discarding the previous upper growth bounds despite holding a supposedly strong order book and healthy lead pipeline.

Conflicting Reasons for Construction Chemicals Slowdown · 21 November 2025. Within the November 2025 call, management provided two different primary reasons for the 6% H1 FY26 revenue decline in the Construction Chemicals business. The CFO first attributed the weakness to an external, temporary factor ('prolonged monsoon'). However, the Chairman later stated the slowdown was a deliberate internal strategic choice to prioritize credit quality and margins over sales growth. Later call (Nov 2025): “This first half year, that is Quarter 1 and Quarter 2, sales were mostly affected by the prolonged monsoon, but the trend is now on a growing side, so we hope H2 would be much better than H1.” Later call (Nov 2025): “The construction business, we were slow because we wanted to be very, very tight on the bottom line and the credit quality.”

Every quote above is taken word for word from the company’s own earnings calls.

Frequently asked questions